Matching articles for "Demadex"
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are...
Patients with a left ventricular ejection fraction (LVEF)
≤40% are considered to have heart failure with reduced
ejection fraction (HFrEF). Patients with a LVEF ≤50%
and symptoms of heart failure are considered to have
heart failure with preserved ejection fraction (HFpEF).
There is little evidence that drug treatment improves
clinical outcomes in patients with HFpEF.
Expanded Table: Some Drugs for HFrEF (online only)
The Medical Letter on Drugs and Therapeutics • April 8, 2019; (Issue 1569)
...
View the Expanded Table: Some Drugs for HFrEF
Sacubitril/Valsartan (Entresto) for Heart Failure
The Medical Letter on Drugs and Therapeutics • August 3, 2015; (Issue 1474)
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular...
The FDA has approved Entresto (Novartis), an oral
fixed-dose combination of the neprilysin inhibitor
sacubitril and the angiotensin receptor blocker (ARB)
valsartan, to reduce the risk of cardiovascular death
and heart failure hospitalization in patients with
heart failure with reduced ejection fraction. Sacubitril
is the first neprilysin inhibitor to become available in
the US.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 19, 2015; (Issue 1460)
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure...
Heart failure is usually associated with left ventricular
dysfunction. According to recent guidelines, patients
with a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF) or systolic heart failure. Patients
with a LVEF ≥50% and symptoms of heart failure
are considered to have heart failure with preserved
ejection fraction (HFpEF) or diastolic heart failure;
there is little evidence that drug treatment improves
clinical outcomes in these patients. The treatment of
acute heart failure is not included here.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • September 1, 2012; (Issue 121)
Chronic systolic heart failure is usually associated with
a left ventricular ejection fraction (LVEF) of ≤40%.
Many patients with symptoms of heart failure have
higher ejection fractions, but there is no...
Chronic systolic heart failure is usually associated with
a left ventricular ejection fraction (LVEF) of ≤40%.
Many patients with symptoms of heart failure have
higher ejection fractions, but there is no evidence that
drug treatment of heart failure with preserved systolic
function (LVEF >40%) improves clinical outcomes.
Some of the drugs commonly used now for treatment of
chronic heart failure are listed in the table on page 71.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • January 1, 2012; (Issue 113)
Drugs available in the US for treatment of chronic
hypertension, with their dosages and adverse effects,
are listed in the tables that begin on page 2.
Combination products are listed on page 8. Drugs...
Drugs available in the US for treatment of chronic
hypertension, with their dosages and adverse effects,
are listed in the tables that begin on page 2.
Combination products are listed on page 8. Drugs for
treatment of hypertensive emergencies are not discussed
here. They were reviewed previously.
Drugs for Treatment of Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • July 1, 2009; (Issue 83)
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as...
The range of drugs for treatment of chronic heart failure continues to expand. Some of those commonly used now are listed in the table on page 55. Mechanical therapies for the treatment of heart failure such as cardiac resynchronization, implanted cardiac defibrillators (ICDs), ventricular assist devices and ultrafiltration for the relief of congestion will not be reviewed here.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • January 1, 2009; (Issue 77)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 2. Combination products are listed on page 9. Drugs for treatment of hypertensive emergencies are not discussed here. They were reviewed in Treatment Guidelines (volume 1, page 19, December 2002) and in The Medical Letter (volume 50, page 73, September 22, 2008).
Drugs for Treatment of Heart Failure
The Medical Letter on Drugs and Therapeutics • January 1, 2006; (Issue 41)
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the...
The choice of drugs for treatment of chronic heart failure continues to evolve. Those most commonly used now are listed in the table on page 3. The use of implanted cardiac defibrillators (ICDs) to reduce the incidence of sudden death in patients with heart failure and the treatment of decompensated heart failure were discussed in previous issues.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • June 1, 2005; (Issue 34)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the tables that begin on page 40. Combination products are listed on page 47. Drugs for treatment of hypertensive emergencies are not discussed here.
Drugs for Treatment of Heart Failure
The Medical Letter on Drugs and Therapeutics • April 1, 2003; (Issue 8)
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as...
The choice of drugs for treatment of chronic heart failure continues to evolve. It has become increasingly recognized that drugs used in heart failure produce beneficial effects through neurohormonal as well as hemodynamic mechanisms. The treatment of decompensated heart failure is not discussed here; drugs used for this indication were reviewed in Cardiovascular Drugs in the ICU, Treatment Guidelines from The Medical Letter 2002; 1:19.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • February 1, 2003; (Issue 6)
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs...
Drugs available in the US for treatment of chronic hypertension, with their dosages, adverse effects and costs, are listed in the table that begins on page 35. Combination products are listed on page 39. Drugs for treatment of hypertensive emergencies were discussed in Treatment Guidelines volume 1, issue 4, page 19, December 2002.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • March 5, 2001; (Issue 1099)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • March 12, 1999; (Issue 1048)
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the...
Drugs available in the USA for treatment of chronic hypertension, their dosages and adverse affects are listed in the table and discussed in the text.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • January 29, 1999; (Issue 1045)
...
The choice of drugs for treatment of heart failure depends on both hemodynamic and neurohormonal factors.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • October 11, 1996; (Issue 985)
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on...
Cardiologist now emphasize the importance of neurohormonal as well as hemodynamic factors in the pathophysiology of chronic heart failure (JN Cohn, N Engl J Med, 335:490, August 15, 1996). Drugs that act on different mechanisms are commonly used together.
Torsemide (Demadex) - A New Loop Diuretic
The Medical Letter on Drugs and Therapeutics • August 19, 1994; (Issue 929)
Torsemide, a new loop diuretic similar in action to bumetanide (Bumex) and furosemide, was recently approved by the US Food and Drug Administration for treatment of edema due to congestive heart failure, renal...
Torsemide, a new loop diuretic similar in action to bumetanide (Bumex) and furosemide, was recently approved by the US Food and Drug Administration for treatment of edema due to congestive heart failure, renal disease, or hepatic disease and also for treatment of hypertension. It is available for both oral and intravenous use.